Where I see patients (1)
My reviews
Selected research
-
Emerging immunotherapies in the Hodgkin lymphoma armamentarium.
Expert opinion on emerging drugs
-
The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Leukemia research
-
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
Blood advances
Clinical trials
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
To determine the ctDNA/MRD negative, PET negative complete response rate for cHL, participants undergoing treatment with pembro + GVD will have a composite response incorporating the following two criteria: (1) Absence of detectab...
Recruiting
4.9